Number 65 Demonstrates Leadership Daniel Olszta, Joliet Oncology Hematology Associates, delivers on the National Community Oncology Dispensing Association’s mission… Passion for Patients. This article poignantly describes one mans’ battle with the current healthcare system. It was written in October 2017 by former Joliet, IL Herald-News reporter and editor Bill Wimbiscus. He can be reached at […]

Oncologists, Nurses, Pharmacy Technicians, Pharmacists, and Other Professionals Attend 2nd Annual Forum in Dallas The National Community Oncology Dispensing Association, Inc (NCODA) welcomed 165 oncology healthcare professionals representing more than 100 practices to its second annual NCODA Forum in Dallas, TX, March 1-3. A diverse group of professionals, including nurses, pharmacists, pharmacy techs, oncologists, administrators, […]

MISSION STATEMENT/PHILOSOPHY The physicians, staff and management of Utah Cancer Specialists are dedicated to the diagnosis, treatment and management of all forms of cancer and blood related diseases.  UCS is dedicated to helping people with these diseases achieve optimum health and quality of life through excellence in the delivery of compassionate medical care.  UCS understands […]

Financial toxicity has become an urgent issue in the field of oncology due to the ever-growing number of patients having difficulty paying for their complex oncolytic treatments. This financial toxicity can lead to a decrease in adherence to cancer therapy. In January 2013 Hematology-Oncology Associates of Central New York (HOACNY), East Syracuse, N.Y., made the […]

Mission Statement Meeting and exceeding the needs of our patients is our primary goal. We recognize that each patient is an individual with unique needs. Our staff is dedicated to the fight against cancer and providing A New Way of Caring.

By Joshua Nubla, PharmD; Neal Dave, PharmD; and Michael Reff, RPh, MBA An in-depth look into a nationwide collaborative initiative to standardize and improve oncology dispensing practices for the benefit of patient/provider education, adherence, and overall care. Care for patients in the oncology setting is extremely diverse and complex. Management of the many distinct oral […]

A letter from members of the U.S. Congress urging the U.S. Department of Health and Human Services (HHS) and Centers for Medicare & Medicaid Services (CMS) to "work within existing authority to ensure Medicare Part D plan sponsors dedicate a meaningful share of negotiated rebates, discounts, and other fees to reduce Part D patients’ out-of […]

The collaboration aims to spread awareness of the growing need for dispensing cancer clinics CRANBURY, N.J.–(BUSINESS WIRE)–OncLive®, a leading digital provider of resources and information to oncology professionals, has teamed up with the National Community Oncology Dispensing Association (NCODA) through its Strategic Alliance Partnership (SAP) program. “Teaming up with the National Community Oncology Dispensing Association […]

Written by: Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates Download Here For patients with Non‐Small Cell Lung Cancer (NSCLC) that have sensitizing epidermal growth factor receptor (EGFR) mutations (most commonly exon 19 deletions or exon 21 L858R mutations) appropriate for first‐line treatment with an EGFR inhibitor, osimertinib (Tagrisso) has a clear progression free survival […]

Written by Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates Download Here Description: Chronic Lymphocytic Leukemia (CLL) diagnosis with the chromosomal abnormality of 17p Deletion is associated with a poor prognosis.  The 17p deletion is found 3‐10% of the time at diagnosis, but 30‐ 50% at relapse.   Testing rates at diagnosis and especially relapse are low.  Venetoclax is […]